Open Nipple Sparing Mastectomy (NSM) (NSM Open)
A Retrospective, Multicenter Study of Open Nipple Sparing Mastectomy (NSM)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Tish Mikoczi
- Phone Number: 760-274-5811
- Email: tish.mikoczi@intusurg.com
Study Contact Backup
- Name: Cheryl Baclit
Study Locations
-
-
Illinois
-
Evanston, Illinois, United States, 60201
- NorthShore University Health System
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Hosp - Methodist Campus - MN
-
-
New York
-
Queens, New York, United States, 11040
- Northwell Health
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Pennsylvania Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- Univ. of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
All female patients that have undergone open prophylactic NSM cases performed between January 1, 2018 through 42 days prior to IRB approval
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Open
Prophylactic NSM cases by Open approach
|
Prophylactic open NSM procedures
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety Endpoint: complication rate
Time Frame: IntraOperative period through 42 days postoperatively
|
To assess the number of open prophylactic nipple sparing mastectomy complications compared to the number of procedures
|
IntraOperative period through 42 days postoperatively
|
|
Effectiveness
Time Frame: IntraOperative period through 42 days postoperatively
|
Ability to completely excise memory gland tissue and preserve Nipple Areola Complex
|
IntraOperative period through 42 days postoperatively
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ISI-RoNSM-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nipple Sparing Mastectomy
-
NCT03892980Active, not recruitingNipple Sparing Mastectomy
-
NCT05251285TerminatedProphylactic Nipple Sparing Mastectomy (NSM)
-
NCT06073808Not yet recruitingMastectomy | Nipple Sparing Mastectomy | Prophylactic Mastectomy | Gender Affirmation Surgery | Benign Breast Condition
-
NCT06748677RecruitingRobotic Surgery | Endoscopic Surgery | Nipple-sparing Mastectomy | Immediate Prosthesis Reconstruction
-
NCT04596683UnknownBreast Cancer | Mastectomy; Lymphedema | Nipple-sparing Mastectomy | Same Day Surgery | Skin-sparing Mastectomy
-
NCT05917834CompletedBreast Cancer | Nipple Sparing Mastectomy
-
NCT06629012Active, not recruitingBreast Reconstruction | Breast Cancer Patients | Nipple-sparing Mastectomy
-
NCT05448963Active, not recruitingBreast Cancer | BRCA1 Mutation | BRCA2 Mutation | Nipple-sparing Mastectomy | Prophylactic Mastectomy
-
NCT07579117RecruitingBreast Surgery | Breast Cancer | Endoscopic Video-assisted Nipple-sparing Mastectomy
-
NCT07261904RecruitingReconstruction of the Nipple-areola Complex in Patients Undergoing Breast Reconstructive Surgery Following Mastectomy
Clinical Trials on Nipple Sparing Mastectomy
-
NCT04585074Active, not recruitingBreast Neoplasms | Benign Breast Disease | Germline BRCA1 Gene Mutation | Germline BRCA2 Gene Mutation | Germline Mutation Abnormality
-
NCT04037852Recruiting
-
NCT04108117CompletedRecurrence | Postoperative Complications | Breast Cancer | Breast Neoplasms | Surgery | Surgery--Complications | BRCA1 Mutation | BRCA2 Mutation
-
NCT05490433RecruitingBreast Cancer Classified as TNM Stage 0-IIIa
-
NCT04049305Unknown
-
NCT01002014CompletedBreast Cancer | Breast Reconstruction | Cosmesis
-
NCT04640454Completed
-
NCT05251285TerminatedProphylactic Nipple Sparing Mastectomy (NSM)
-
NCT03470909Completed
-
NCT07230535RecruitingRobotic Surgery | Breast Reconstruction | DIEP Flap Breast Reconstruction | Breast Cancer, Breast Neoplasms